<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598052</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-7.1.08-CTIL</org_study_id>
    <secondary_id>Sponsored by IADA</secondary_id>
    <nct_id>NCT00598052</nct_id>
  </id_info>
  <brief_title>Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy</brief_title>
  <official_title>Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy- a Double-Blind Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have established the reliability, validity and time course of the cannabis
      withdrawal syndrome. This study will investigate the effects of combined treatment of
      Escitalopram with cognitive-behavior therapy in alleviating the symptoms of the marijuana
      withdrawal syndrome in regular chronic users of marijuana. We predict that combined
      pharmacological treatment and cognitive-behavior therapy will help patients to abstain from
      using using marijuana and it will alleviate their marijuana withdrawal symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies have established the reliability, validity and time course of the cannabis
      withdrawal syndrome characterized by symptoms of anxiety, irritability, negative mood,
      physical symptoms and decreased appetite. This study will investigate the effects of combined
      treatment of Escitalopram with cognitive-behavior therapy in alleviating the symptoms of the
      marijuana withdrawal syndrome in regular chronic users of marijuana. 40 patients will be
      blindly randomized to either active or placebo escitalopram 10mg/day, for 12 weeks followed
      bt 12 weeks of follow-up.

      Inclusion criteria include:

        -  Men and women age 20-45

        -  DSM-IV diagnosis of THC dependence.

      Exclusion criteria include:

        -  Dependence on other drugs or alcohol

        -  Bipolar Disorder or Schizophrenia, Major depression, suicidal ideation psychotic
           symptoms or violent thoughts

        -  Current treatment with anti-depressant medication

        -  Neurological disease

        -  Physical illness (hypothyroidism, severe anemia, renal failure)

        -  Past severe effects of SSRIs.

      Outcome measures include:

        -  urine THC analysis every two weeks

        -  questionnaires assessing addiction severity index

        -  depression and anxiety.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">October 2008</completion_date>
  <primary_completion_date type="Anticipated">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clean urine THC samples</measure>
    <time_frame>Every 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire ratings of anxiety and depression and withdrawal symptoms</measure>
    <time_frame>Every week of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Marijuana Dependence</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Escitalopram + cognitive-behavior treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + cognitive-behavior therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10mg/day</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Cipralex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 20-45

          -  DSM IV criteria of marijuana dependence.

        Exclusion Criteria:

          -  Other drug or alcohol dependence

          -  Bipolar disorder, schizophrenia, major depression, suicidal ideation, psychotic
             symptoms or violent thoughts

          -  Physical illness including hypothyroidism, neurological disease, severe anemia, and
             renal failure

          -  Past severe side effects of SSRIs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miki Bloch, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sourasky Medical center, Tel Aviv</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aviv M Weinstein, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sourasky Medical Center Tel Aviv, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aviv M Weinstein, Ph.D</last_name>
    <phone>97236973685</phone>
    <email>avivmw@tasmc.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eti Tal, B.A</last_name>
    <phone>97236973685</phone>
    <email>etital10@walla.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irit Ben-Avi, Ph.D</last_name>
      <phone>97236973685</phone>
      <email>iritbe@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Eti Tal, B.A</last_name>
      <phone>97236973685</phone>
      <email>etital10@walla.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aviv M Weinstein, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miki Bloch, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2008</study_first_posted>
  <last_update_submitted>March 30, 2008</last_update_submitted>
  <last_update_submitted_qc>March 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Miki Bloch</name_title>
    <organization>Sourasky Medical center</organization>
  </responsible_party>
  <keyword>Marijuana dependence withdrawal Escitalopram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

